Plasma immune analytes in patients with epithelial ovarian cancer

Cytokine

Volumn 73, Issue 1, 2015, Pages 108-113

  Block, Matthew S ^a,b   Maurer, Matthew J ^a   Goergen, Krista ^a   Kalli, Kimberly R ^a   Erskine, Courtney L ^b   Behrens, Marshall D ^b   Oberg, Ann L ^a   Knutson, Keith L ^b,c  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c Vaccine and Gene Therapy Institute   (United States)

Author keywords

HSP90B1; Interleukin 6 (IL 6); Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; GAMMA INTERFERON; HEAT SHOCK PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PLACENTAL GROWTH FACTOR; PROTEIN HSP90B1; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CYTOKINE; GLUCOSE REGULATED PROTEIN 94; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER STAGING; CHEMOLUMINESCENCE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; BLOOD; IMMUNOLOGY; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY; STATISTICAL MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CA-125 ANTIGEN; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; LOGISTIC MODELS; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 84924040504     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.01.035     Document Type: Article

References (41)

1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011. CA Cancer J Clin 2011, 61:212-236.
2. Mayer A.R., Chambers S.K., Graves E., Holm C., Tseng P.C., Nelson B.E., et al. Ovarian cancer staging: does it require a gynecologic oncologist?. Gynecol Oncol 1992, 47:223-227.
3. Kadija S, Stefanovic A, Jeremic K, Radojevic MM, Nikolic L, Markovic I, Atanackovic J. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol Cancer 2011. Publish Ahead of Print:10.1097/IGC.1090b1013e318234f318852.
4. Karlsen M.A., Sandhu N., Hogdall C., Christensen I.J., Nedergaard L., Lundvall L., et al. Evaluation of he4, ca125, risk of ovarian malignancy algorithm (roma) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2012, 127:379-383.
5. Moore R.G., Jabre-Raughley M., Brown A.K., Robison K.M., Miller M.C., Allard W.J., et al. Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010, 203(228):e221-e226.
6. Canney P.A., Moore M., Wilkinson P.M., James R.D. Ovarian-cancer antigen ca125-a prospective clinical-assessment of its role as a tumor-marker. Br J Cancer 1984, 50:765-769.
7. Niloff J.M., Knapp R.C., Schaetzl E., Reynolds C., Bast R.C. Ca125-antigen levels in obstetric and gynecologic patients. Obstet Gynecol 1984, 64:703-707.
8. Wang Y., Cheon D.J., Lu Z., Cunningham S.L., Chen C.M., Luo R.Z., et al. Muc16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. Differentiation 2008, 76:1081-1092.
9. Dodge J.E., Covens A.L., Lacchetti C., Elit L.M., Le T., Devries-Aboud M., et al. Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. Gynecol Oncol 2012, 126:157-166.
10. Hellstrom I., Raycraft J., Hayden-Ledbetter M., Ledbetter J.A., Schummer M., McIntosh M., et al. The he4 (wfdc2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003, 63:3695-3700.
11. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral t cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213.
12. Nelson B.H. The impact of t-cell immunity on ovarian cancer outcomes. Immunol Rev 2008, 222:101-116.
13. Piura B., Piura E. Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma. J Oncol 2009, 2009:581939.
14. Maccio A., Madeddu C. The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications-a review. J Mol Med 2013, 91:1355-1368.
15. Dobrzycka B., Terlikowski S.J., Kowalczuk O., Kinalski M. Circulating levels of tnf-alpha and its soluble receptors in the plasma of patients with epithelial ovarian cancer. Eur Cytokine Netw 2009, 20:131-134.
16. Geisler J.P., Geisler H.E., Tammela J., Wiemann M.C., Zhou Z., Miller G.A., et al. Heat shock protein 27: an independent prognostic indicator of survival in patients with epithelial ovarian carcinoma. Gynecol Oncol 1998, 69:14-16.
17. Lawicki S., Bedkowska G.E., Gacuta-Szumarska E., Szmitkowski M. The plasma concentration of vegf, he4 and ca125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. J Ovarian Res 2013, 6:45.
18. Edge S.B., Byrd D.R., Compton C.C., Fritz A.G., Greene F.L., Trotti A. American joint committee on cancer (AJCC) cancer staging manual 2010, Springer, Inc., Chicago. 7th ed.
19. Wu A.H., Pearce C.L., Tseng C.C., Templeman C., Pike M.C. Markers of inflammation and risk of ovarian cancer in Los Angeles county. Int J Cancer 2009, 124:1409-1415.
20. Toriola A.T., Grankvist K., Agborsangaya C.B., Lukanova A., Lehtinen M., Surcel H.M. Changes in pre-diagnostic serum c-reactive protein concentrations and ovarian cancer risk: a longitudinal study. Ann Oncol 2011, 22:1916-1921.
21. Berek J.S., Chung C., Kaldi K., Watson J.M., Knox R.M., Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1991, 164:1038-1042. [discussion 1042-1033].
22. Scambia G., Testa U., Panici P.B., Martucci R., Foti E., Petrini M., et al. Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer 1994, 57:318-323.
23. van der Poll T., Keogh C.V., Guirao X., Buurman W.A., Kopf M., Lowry S.F. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis 1997, 176:439-444.
24. Pedersen B.K., Febbraio M.A. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 2008, 88:1379-1406.
25. Easton R., Balogh Z.J. Peri-operative changes in serum immune markers after trauma: a systematic review. Injury 2014, 45:934-941.
26. Bode J.G., Albrecht U., Haussinger D., Heinrich P.C., Schaper F. Hepatic acute phase proteins-regulation by il-6-and il-1-type cytokines involving stat3 and its crosstalk with nf-kappab-dependent signaling. Eur J Cell Biol 2012, 91:496-505.
27. Johnson J.L., Moore E.E., Tamura D.Y., Zallen G., Biffl W.L., Silliman C.C. Interleukin-6 augments neutrophil cytotoxic potential via selective enhancement of elastase release. J Surg Res 1998, 76:91-94.
28. Kopf M., Ramsay A., Brombacher F., Baumann H., Freer G., Galanos C., et al. Pleiotropic defects of il-6-deficient mice including early hematopoiesis, t and b cell function, and acute phase responses. Ann N Y Acad Sci 1995, 762:308-318.
29. Scambia G., Testa U., Benedetti Panici P., Foti E., Martucci R., Gadducci A., et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 1995, 71:354-356.
30. Duan Z., Foster R., Bell D.A., Mahoney J., Wolak K., Vaidya A., et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 2006, 12:5055-5063.
31. Nilsson M.B., Langley R.R., Fidler I.J. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 2005, 65:10794-10800.
32. Coward J., Kulbe H., Chakravarty P., Leader D., Vassileva V., Leinster D.A., et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011, 17:6083-6096.
33. Wolf J., Rose-John S., Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 2014, 70:11-20.
34. Kovacs E. Investigation of interleukin-6 (il-6), soluble il-6 receptor (sil-6r) and soluble gp130 (sgp130) in sera of cancer patients. Biomed Pharmacother 2001, 55:391-396.
35. Lo C.W., Chen M.W., Hsiao M., Wang S., Chen C.A., Hsiao S.M., et al. Il-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res 2011, 71:424-434.
36. Aune G., Stunes A.K., Lian A.M., Reseland J.E., Tingulstad S., Torp S.H., et al. Circulating interleukin-8 and plasminogen activator inhibitor-1 are increased in women with ovarian carcinoma. Res Immunol 2012, 2:190-195.
37. Wertel I., Polak G., Tarkowski R., Kotarska M. Evaluation of il-10 and tgf-beta levels and myeloid and lymphoid dendritic cells in ovarian cancer patients. Ginekol Pol 2011, 82:414-420.
38. Gadducci A., Ferdeghini M., Castellani C., Annicchiarico C., Gagetti O., Prontera C., et al. Serum levels of tumor necrosis factor (tnf), soluble receptors for tnf (55- and 75-kda stnfr), and soluble cd14 (scd14) in epithelial ovarian cancer. Gynecol Oncol 1995, 58:184-188.
39. Kim Y.J., Lee S.A., Myung S.C., Kim W., Lee C.S. Radicicol, an inhibitor of hsp90, enhances trail-induced apoptosis in human epithelial ovarian carcinoma cells by promoting activation of apoptosis-related proteins. Mol Cell Biochem 2012, 359:33-43.
40. Thuringer D., Hammann A., Benikhlef N., Fourmaux E., Bouchot A., Wettstein G., et al. Transactivation of the epidermal growth factor receptor by heat shock protein 90 via toll-like receptor 4 contributes to the migration of glioblastoma cells. J Biol Chem 2011, 286:3418-3428.
41. Elstrand M.B., Stavnes H.T., Trope C.G., Davidson B. Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions. Hum Pathol 2012, 43:529-535.